Multi-modality: A new approach for the treatment of major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 16, Issue 6, 2013, Pages 1433-1442

  Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antidepressant; brexpiprazole; MDD; multi modal therapy; vilazodone; vortioxetine

Indexed keywords

1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; AMFEBUTAMONE; AMITIFADINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BREXPIPRAZOLE; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PINDOLOL; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VILAZODONE; VORTIOXETINE;

ANXIETY DISORDER; ARTICLE; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG NOMENCLATURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SLEEP DISORDER; SOMNOLENCE; THERAPY EFFECT; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 84878877345     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001605     Document Type: Article

References (74)

1. Airaksinen E, Larsson M, Lundberg I, Forsell Y (2004) Cognitive functions in depressive disorders: Evidence from a population-based study. Psychol Med 34:83-91.
2. Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284-291.
3. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2011) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15:589-600.
4. Artigas F, Romero L, De Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-383.
5. Ashton K, Jamerson BD, Weinstein WL, Wagoner C (2005) Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res 66:96-106.
6. Baldwin DS, Loft H, Dragheim M (2012) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 22:482-491.
7. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Fredericksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB (2011) Discovery of 1-[2-(2,4- dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206-3221.
8. Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Perahia DG, Reed C, Tyee A (2008) Prescribing patterns of antidepressants in Europe: Results from the factors influencing depression endpoints research (FINDER) study. Eur Psychiatry 23:66-73.
9. Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N (2012) The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine invovles 5-HT3 receptor antagonism. Int J Neuropsychopharmacol. Advance online publication. Retrieved 22 October 2012. doi:10.1017/ S1461145712001058.
10. Blier P, Gobbi G, Turcotte JE, De Montigny C, Boucher N, Hébert C, Debonnel G (2009) Mirtazapine and paroxetine in major depression: a comparison of monotherapy vs. their combination from treatment initiation. Eur Neuropsychopharmacol 19:457-465.
11. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R (2010) Combination of antidepressant medications from treatment initiation for major depressive disorder : A double-blind randomized study. Am J Psychiatry 167:281-288.
12. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31:5-19.
13. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW (2002) Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36:578-584.
14. Casacalenda N, Boulenger JP (1998) Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder : Clinical and theoretical implications. Can J Psychiatry 43:722-730.
15. Cascade EF, Kalali AH, Blier P (2007) Treatment of depression: antidepressant monotherapy and combination therapy. Psychiatry (Edgmont) 4:25-27.
16. Chancellor D (2011) The depression market. Nat Rev Drug Discov 10:809-810.
17. Chang T, Fava M (2010) The future of psychopharmacology of depression. J Clin Psychiatry 71:971-975.
18. Dawson LA, Watson JM (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 15:107-117.
19. de Boer SF, Koolhaas JM (2005) 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol 526:125-139.
20. DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV (2011) SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med 52:1150-1155.
21. Dodd S, Horgan D, Malhi GS, Berk M (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89:1-11.
22. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders : Implications for neurocircuitry models of depression. Brain Struct Funct 213:93-118.
23. Dunlop BW, Davis PG (2008) Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim Care Companion J Clin Psychiatry 10:222-228.
24. Fava M (2009) Augmentation and combination strategies for complicated depression. J Clin Psychiatry 70:e400
25. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI (2006) A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 67:1754-1759.
26. Fone KC (2008) An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55:1015-1022.
27. Golembiowska K, Kowalska M, Bymaster FP (2012) Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse 66:435-444.
28. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Abarca JE, Herrera-Guzman D, Montelongo-Pedraza P, Padrós Blázquez F, Peró-Cebollero M, Guardia-Olmos J (2010) Major depressive disorder in recovery and neuropsychological functioning : Effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J Affect Disord 123:341-350.
29. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 43:855-863.
30. Howland RH, Thase ME (2005) Comorbid depression and anxiety : When and how to treat. J Psychiatry 329:891-1047.
31. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG (1996) Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US National Comorbidity Survey. Br J Psychiatry 168(Suppl. 30) :17-30.
32. Khan A (2009) Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 18:1753-1764.
33. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72:464-472.
34. Landén M, Eriksson E, Agren H, Fahlén T (1999) Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 19:268-271.
35. Langlieb AM, Guico-Pabia CJ (2010) Beyond symptomatic improvement : Assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry 12:pii : PCC.09r00826.
36. Laughren TP, et al. (2011) Vilazodone: Clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 72:1166-1173.
37. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer GM Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E (2012) Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder : Two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol 26:653-662.
38. Liang Y, Richelson E (2008) Triple reuptake inhibitors : Next-generation antidepressants. Prim Psychiatry 15:50-56.
39. Maes M, Libbrecht I, Van Hunsel F, Campens D, Melter HY (1999) Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19:177-182.
40. Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J (2007) Neurobiology of depression: an integrated view of key findings. Int J Clin Pract 61:2030-2040.
41. Melander H, Salmonson T, Abadie E, Van Zwieten-Boot B (2008) A regulatory Apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623-627.
42. Meyer JH (2007) Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32:86-102.
43. Millan MJ (2009) Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics 6:53-77.
44. Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67:26-36.
45. Mondal S, Sharma VK, Das S, Goswami U, Ghandi A (2007) Neuro-cognitive functions in patients of major depression. Indian J Physiol Pharmacol 51:69-75.
46. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, Lam RW, Lépine JP, Möller HJ, Nutt DJ, Rouillon F, Schatzber AF, Thase ME (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323-329.
47. Nelson JC (2009) Augmentation and combination strategies in resistant depression. J Clin Psychiatry 70:e200
48. Nelson JC, Mazure CM, Jatlow PI, Bowers Jr. MB, Price LH (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55:296-300.
49. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse : A STAR D report. Psychol Med 40:41-50.
50. Nutt DJ (2009) Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? J Psychopharmacol 23:343-345.
51. Nutt DJ (2010) Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. J Clin Psychiatry 71:e02.
52. Ogren SO, Eriksson TM, Elvander-Tottie E, D'Addario C, Ekstro?m JC, Svenningsson P, Meister B, Kehr J, Stiedl O (2008) The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 195:54-77.
53. Otsuka Pharmaceutical Co Ltd (2011) Press release : Otsuka Pharmaceutical Co Ltd announces results from a Phase 2 study of investigational product OPC-34712 as adjunctive therapy in adults with major depressive disorder. Tokyo, Japan: Otsuka Pharmaceutical Co. Ltd.
54. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62:1217-1227.
55. Porter RJ, Gallagher P, Thompson JM, Young AH (2003) Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 182:214-220.
56. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR (2009) Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder : A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70:326-333.
57. Robinson DS, Rickels K, Feighner J, Fabre LF (1990) Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10:67S-76S.
58. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rararap SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE (2007) Differentiating antidepressants of the future : Efficacy and safety. Pharmacol Ther 113:134-153.
59. Rush AJ (2007) STAR D: What have we learned? AmJ Psychiatry 164:201-204.
60. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, FAVA M, Kurian BT, Warden D, Morris DS, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR (2011) Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689-701.
61. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report. Am J Psychiatry 163:1905-1917.
62. Schreiber R, De Vry J (1993) 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action? Prog Neuro-Psychopharmacol Biol Psychiatry 17:87-104.
63. Sepracor Inc. (2009). Sepracor press release Update on clinical trials for SEP-225289 and LUNESTA pediatrics. Marlborough, MA: Sunovion Pharmaceuticals.
64. Singh M, Schwartz TL (2012) Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat 8 :123-130.
65. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006) Preclinical and clinical pharmacology of DOV 216,303, a 'triple ' reuptake inhibitor. CNS Drug Rev 12:123-134.
66. Stahl SM (2010) Enhancing outcomes from major depression: Using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 15:79-94.
67. Terry Jr. AV, Buccafusco JJ, Wilson C (2008) Cognitive dysfunction in neuropsychiatric disorders : Selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 195:30-38.
68. Thase ME (2009) Pharmacologic and therapeutic strategies in treatment-resistant depression. Augmentation strategies. CNS Spectr 14:7-10.
69. Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH (2010) Remission with mirtazapine and selective serotonin reuptake inhibitors : A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 25:189-198.
70. Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M (2012) Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder : A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 46:64-71.
71. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shors-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 163:28-40.
72. Uher R, Dernovsek MZ, Mors O, Hauser J, Souery D, Zobel A, Maier W, Henigsberg N, Kalember P, Rietschel M, Placentino A, Mendlewucz J, Aitchison KJ, McGuffin P, Farmer A (2011) Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord 132:112-120.
73. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386-392.
74. Waters KA, Stean TO, Hammond B, Virley DJ, Upton N, Kew JN, Hussain I (2012) Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res 228:211-218.